CN103370308B - 缩氨基硫脲化合物和在癌症治疗中的用途 - Google Patents

缩氨基硫脲化合物和在癌症治疗中的用途 Download PDF

Info

Publication number
CN103370308B
CN103370308B CN201180067592.3A CN201180067592A CN103370308B CN 103370308 B CN103370308 B CN 103370308B CN 201180067592 A CN201180067592 A CN 201180067592A CN 103370308 B CN103370308 B CN 103370308B
Authority
CN
China
Prior art keywords
cancer
dp4cych4mt
compounds
dp4e4mt
thiosemicarbazone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180067592.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103370308A (zh
Inventor
德斯·R·里卡德松
大卫·B·洛夫乔伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010905539A external-priority patent/AU2010905539A0/en
Application filed by Individual filed Critical Individual
Publication of CN103370308A publication Critical patent/CN103370308A/zh
Application granted granted Critical
Publication of CN103370308B publication Critical patent/CN103370308B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN201180067592.3A 2010-12-17 2011-12-16 缩氨基硫脲化合物和在癌症治疗中的用途 Expired - Fee Related CN103370308B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2010905539A AU2010905539A0 (en) 2010-12-17 Dipyridyl Thiosemicarbazone compounds and use in therapy
AU2010905539 2010-12-17
PCT/AU2011/001631 WO2012079128A1 (en) 2010-12-17 2011-12-16 Thiosemicarbazone compounds and use in the treatment of cancer

Publications (2)

Publication Number Publication Date
CN103370308A CN103370308A (zh) 2013-10-23
CN103370308B true CN103370308B (zh) 2015-06-17

Family

ID=46243892

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180067592.3A Expired - Fee Related CN103370308B (zh) 2010-12-17 2011-12-16 缩氨基硫脲化合物和在癌症治疗中的用途

Country Status (10)

Country Link
US (1) US8927580B2 (enExample)
EP (2) EP2651894B1 (enExample)
JP (1) JP5883457B2 (enExample)
KR (1) KR20140022786A (enExample)
CN (1) CN103370308B (enExample)
AU (1) AU2011342378B2 (enExample)
BR (1) BR112013015174A2 (enExample)
CA (1) CA2821984A1 (enExample)
NZ (1) NZ613085A (enExample)
WO (1) WO2012079128A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5883457B2 (ja) 2010-12-17 2016-03-15 アール リチャードソン，デ チオセミカルバゾン化合物および癌の治療における使用
US20150306081A1 (en) * 2012-11-22 2015-10-29 Oncochel Therapeutics LLC Chemotherapy for Drug-Resistant Cancer Cells
CN104177288B (zh) * 2013-05-23 2020-05-01 中国人民解放军军事医学科学院毒物药物研究所 缩氨基硒脲衍生物及其药物组合物和用途
US12383518B2 (en) 2013-11-03 2025-08-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Disulfide-masked pro-chelator compositions and methods of use
US11504346B2 (en) 2013-11-03 2022-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Redox-activated pro-chelators
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2017058748A1 (en) * 2015-09-29 2017-04-06 Oncochel Therapeutics, Llc Thiosemicarbazones
CN109052605A (zh) * 2018-07-26 2018-12-21 雷晓琳 一种重金属捕集剂及其制备方法
CN110698511B (zh) * 2019-11-15 2021-09-14 广西师范大学 以2-吡啶甲醛缩氨基硫脲为配体的锡配合物及其合成方法
KR102555030B1 (ko) * 2020-10-19 2023-07-14 고려대학교 산학협력단 티오세미카바존 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4207400A1 (de) * 1992-03-09 1993-09-16 Bayer Ag Hydrazone
CN1764644A (zh) * 2003-02-05 2006-04-26 新南创新私人有限公司 金属离子螯合剂及其医疗用途
CN1891701A (zh) * 2005-07-07 2007-01-10 桑迪亚医药技术（上海）有限责任公司 杂芳环缩氨基硫脲类化合物及其衍生物和它们在制备抗肿瘤药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252798A1 (en) 2003-02-05 2006-11-09 Richardson Desi R Metal ion chelators and therapeutic use thereof
WO2010000008A1 (en) * 2008-06-30 2010-01-07 Desi Raymond Richardson Thiosemicarbazone compounds and use thereof
JP5883457B2 (ja) 2010-12-17 2016-03-15 アール リチャードソン，デ チオセミカルバゾン化合物および癌の治療における使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4207400A1 (de) * 1992-03-09 1993-09-16 Bayer Ag Hydrazone
CN1764644A (zh) * 2003-02-05 2006-04-26 新南创新私人有限公司 金属离子螯合剂及其医疗用途
CN1891701A (zh) * 2005-07-07 2007-01-10 桑迪亚医药技术（上海）有限责任公司 杂芳环缩氨基硫脲类化合物及其衍生物和它们在制备抗肿瘤药物中的应用

Also Published As

Publication number Publication date
JP2014502599A (ja) 2014-02-03
AU2011342378A1 (en) 2013-08-01
AU2011342378B2 (en) 2016-09-01
JP5883457B2 (ja) 2016-03-15
EP2651894A4 (en) 2014-07-09
BR112013015174A2 (pt) 2020-08-11
CN103370308A (zh) 2013-10-23
US20140206725A1 (en) 2014-07-24
WO2012079128A1 (en) 2012-06-21
EP2651894A1 (en) 2013-10-23
US8927580B2 (en) 2015-01-06
KR20140022786A (ko) 2014-02-25
CA2821984A1 (en) 2012-06-21
EP2651894B1 (en) 2017-08-23
EP3287442A1 (en) 2018-02-28
NZ613085A (en) 2015-05-29

Similar Documents

Publication Publication Date Title
CN103370308B (zh) 缩氨基硫脲化合物和在癌症治疗中的用途
US10905701B2 (en) Compositions and methods for inhibiting arginase activity
EP3600270B1 (en) Compounds and compositions for treating hematological disorders
US20160287564A1 (en) Methods of administering glutaminase inhibitors
KR102375288B1 (ko) 대사항암제를 포함하는 항암용 조성물
CN116077631A (zh) 涉及粘液素的疾病治疗
US20210221805A1 (en) Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
US20250090530A1 (en) Combinations for the treatment of cancer
US20250248995A1 (en) Compositions and methods for treating polycythemia
TW202028182A (zh) 用於癌症治療之免疫調節之組合
US20110281814A1 (en) Methods and compositions for treating breast cancer
US20250268878A1 (en) Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds)
US9134329B2 (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell
CN117398372A (zh) Ostarine在抑制NLRP3炎症小体活化中的应用
WO2010000008A1 (en) Thiosemicarbazone compounds and use thereof
JP2024546584A (ja) Ｂｃｌ－２阻害剤、ｗｅｅ－１阻害剤及び他の化学療法剤の三剤療法の組み合わせ
TWI753178B (zh) Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物
JP2019528250A (ja) Ｂｃｌ−２阻害剤とｍｃｌ−１阻害剤との組み合わせ、その使用及び医薬組成物
WO2017058748A1 (en) Thiosemicarbazones
US20240382520A1 (en) Composition for preventing and treating cancer through mitochondrial metabolism regulation containing nanographene structure
JP7579863B2 (ja) 医薬組成物及び組み合わせ物
CN100372535C (zh) 4-吡啶基甲基-酞嗪衍生物在制备治疗骨髓增生异常综合征的药物中的用途
US11684610B2 (en) Pharmaceutical composition including 1,2-naphthoquinone derivative compound for prevention or treatment of solid cancers or blood cancers
CN108299390A (zh) 抗肿瘤化合物dcz0415及其制备方法和应用
EP3854411A1 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150617

Termination date: 20151216

EXPY Termination of patent right or utility model